WO2006128129A3 - Method for treating cancer - Google Patents

Method for treating cancer Download PDF

Info

Publication number
WO2006128129A3
WO2006128129A3 PCT/US2006/020821 US2006020821W WO2006128129A3 WO 2006128129 A3 WO2006128129 A3 WO 2006128129A3 US 2006020821 W US2006020821 W US 2006020821W WO 2006128129 A3 WO2006128129 A3 WO 2006128129A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating cancer
rel
modulate
activity
compounds
Prior art date
Application number
PCT/US2006/020821
Other languages
French (fr)
Other versions
WO2006128129A2 (en
Inventor
John Bertin
Ethan P Grant
Original Assignee
Synta Pharmaceuticals Corp
John Bertin
Ethan P Grant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp, John Bertin, Ethan P Grant filed Critical Synta Pharmaceuticals Corp
Publication of WO2006128129A2 publication Critical patent/WO2006128129A2/en
Publication of WO2006128129A3 publication Critical patent/WO2006128129A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a method for treating cancers using compounds that modulate the activity of c-Rel.
PCT/US2006/020821 2005-05-26 2006-05-26 Method for treating cancer WO2006128129A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68505605P 2005-05-26 2005-05-26
US60/685,056 2005-05-26
US72035705P 2005-09-23 2005-09-23
US60/720,357 2005-09-23

Publications (2)

Publication Number Publication Date
WO2006128129A2 WO2006128129A2 (en) 2006-11-30
WO2006128129A3 true WO2006128129A3 (en) 2008-10-30

Family

ID=37452974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020821 WO2006128129A2 (en) 2005-05-26 2006-05-26 Method for treating cancer

Country Status (1)

Country Link
WO (1) WO2006128129A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323345A1 (en) 2003-05-23 2004-12-16 Zentaris Gmbh New pyridopyrazines and their use as kinase inhibitors
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (en) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators
CL2007003049A1 (en) 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug COMPOUNDS DERIVED FROM 2,4-DIAMINOPIRIMIDINE; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT PROLIFERATIVE DISORDERS.
CA2680796A1 (en) 2007-03-14 2008-09-18 Exelixis, Inc. Inhibitors of the hedgehog pathway
CA2920996A1 (en) 2007-10-19 2009-04-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009089277A2 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
CN101977905B (en) 2008-01-23 2014-07-02 百时美施贵宝公司 4-pyridinone compounds and their use for cancer
EP2244709A4 (en) * 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp Topical formulations for the treatment of psoriasis
LT2300013T (en) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (en) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 Heteroaryl compounds and uses thereof
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US8389718B2 (en) 2010-07-20 2013-03-05 Vestaron Corporation Insecticidal triazines and pyrimidines
CA2807051A1 (en) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
RU2013120966A (en) 2010-10-08 2014-11-20 Эббви Инк. FURO [3,2-d] Pyrimidine Compounds
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP5957003B2 (en) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Mutant selective EGFR inhibitor and use thereof
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
CN103501612B (en) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 The compound that cell is bred in cancer caused by suppression EGF-R ELISA
PT2771342T (en) 2011-10-28 2016-08-17 Novartis Ag Purine derivatives and their use in the treatment of disease
TW201325593A (en) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc Methods of treating a BRUTON'S tyrosine kinase disease or disorder
KR20190007106A (en) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
KR102090453B1 (en) 2012-03-15 2020-03-19 셀젠 카르 엘엘씨 Salts of an epidermal growth factor receptor kinase inhibitor
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
US9499561B2 (en) * 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds
JP6411342B2 (en) 2013-07-03 2018-10-24 武田薬品工業株式会社 Amide compounds
LT3024819T (en) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6452119B2 (en) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Carboxamide derivatives and their use as pharmaceuticals for the treatment of hepatitis B
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN106659716B (en) * 2014-01-24 2021-03-12 人工智能治疗公司 Apilimod compositions and methods of use thereof
EP3102225B1 (en) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
CN110483484A (en) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2016073884A1 (en) * 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
CN107249638B (en) * 2014-11-07 2021-05-14 人工智能治疗公司 Use of apilimod for treating kidney cancer
WO2016118709A1 (en) 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
CN106146361A (en) * 2015-03-16 2016-11-23 四川大学 Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use
WO2016149581A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HUE057041T2 (en) 2015-07-06 2022-04-28 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
TWI746449B (en) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 Methods for treating cancer using apilimod
CN105130907B (en) * 2015-07-29 2018-10-16 沈阳药科大学 Pyrimidines and application thereof
TW201718496A (en) 2015-09-29 2017-06-01 諾維拉治療公司 Crystalline forms of a hepatitis B antiviral agent
CR20180323A (en) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
US20190015421A1 (en) * 2016-01-21 2019-01-17 Lam Therapeutics, Inc. Biomarkers for Treating Cancer with Apilimod
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
EP3503925A1 (en) 2016-08-25 2019-07-03 AI Therapeutics, Inc. Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling
RU2019113752A (en) 2016-10-12 2020-11-13 ЭйАй ТЕРАПЬЮТИКС, ИНК. APILIMOD COMPOSITIONS AND METHODS OF THEIR USE IN TREATMENT OF ALZHEIMER'S DISEASE
PL3570834T3 (en) 2017-01-11 2022-05-23 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10702534B2 (en) 2017-03-31 2020-07-07 AI Therapeutics, Inc. Compositions and methods relating to the radioprotective effects of apilimod
DK3625222T3 (en) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS
MX2019013639A (en) 2017-05-18 2020-01-21 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives.
TW201900179A (en) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 Benzofuran and benzothiophene derivatives as PGE2 receptor modulators
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
HUE056382T2 (en) 2017-05-18 2022-02-28 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
RS63343B1 (en) 2017-08-07 2022-07-29 Alkermes Inc Bicyclic inhibitors of histone deacetylase
US20200199136A1 (en) 2017-08-28 2020-06-25 Acurastem Inc. Pikfyve kinase inhibitors
MX2020008680A (en) 2018-02-21 2020-09-25 Ai Therapeutics Inc Combination therapy with apilimod and glutamatergic agents.
CN111867582A (en) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 Capsid assembly modulator dosing regimen
MA55020A (en) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS
JP2022532526A (en) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Amide derivatives useful in the treatment of HBV infections or HBV-induced diseases
PE20220597A1 (en) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc PHENYLAMINOPYRIMIDINE AMIDE INHIBITORS OF AUTOPHAGY AND METHODS OF USE OF SUCH
TW202108574A (en) 2019-05-10 2021-03-01 美商迪賽孚爾製藥有限公司 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
WO2020257180A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
KR20220028075A (en) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20210077500A1 (en) 2019-09-12 2021-03-18 Al Therapeutics, Inc. Pikfyve inhibitors for cancer therapy
US20210244743A1 (en) 2020-02-07 2021-08-12 Al Therapeutics, Inc. Anti-viral compositions and methods of use
US20230135152A1 (en) 2020-02-11 2023-05-04 AcuraStem Incorporated Pikfyve kinase inhibitors
MX2022013838A (en) 2020-05-04 2023-02-22 Amgen Inc Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use.
TW202208355A (en) 2020-05-04 2022-03-01 美商安進公司 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022067462A1 (en) * 2020-09-29 2022-04-07 Beigene (Beijing) Co., Ltd. Process for preparing inhibitors of kras g12c
MX2023003995A (en) 2020-10-05 2023-06-12 Enliven Inc 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases.
CN117529324A (en) 2021-06-11 2024-02-06 奥夫艾治疗公司 Stable apilimod compositions and uses thereof
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023215133A1 (en) 2022-05-02 2023-11-09 AcuraStem Incorporated Pikfyve kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEHATA M. ET AL.: "Dual Apoptotic Effect of Xrel3-c-Rel/NF-kappaB Homolog in Human Cervical Cancer Cells", CELL BIOLOGY INTERNATIONAL, vol. 28, no. 12, 2004, pages 895 - 904, XP004654766 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Also Published As

Publication number Publication date
WO2006128129A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006128129A3 (en) Method for treating cancer
EP1909854A4 (en) Method for treating cancer
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
IL197914A (en) Anti-ereg antibodies for treating cancer
EP1934603A4 (en) Biomarker for prostate cancer
IL178920A0 (en) Treatment for pancreatic cancer
GB2435169B (en) Process for treating an underground formation
ZA200709620B (en) Methods for treating drug resistant cancer
HK1115295A1 (en) Methods for treating adhesive capsulitis
PT1830847E (en) Treatment for cancer
EP1862804A4 (en) Method for diagnosis of prostate cancer
IL178578A (en) Desulphatohirudin or desulphatohirudin variant for effecting regression of tumor
EP1833511A4 (en) Method of treating brain cancer
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer
EP2029172A4 (en) Anti-c35 antibodies for treating cancer
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
EP2068911A4 (en) Methods for treating cancer
GB0413346D0 (en) Treating cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0608357D0 (en) Method for treating effluent
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
AU2005903890A0 (en) Method for treating cancer
AU2007906570A0 (en) Compounds for treating cancer
HU0500612D0 (en) Treating apparatus for preventing cancer
GB0503566D0 (en) Treatment for cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06771527

Country of ref document: EP

Kind code of ref document: A2